Zhang Yan, Yu Huijin, Shao Kangmei, Luo Xinyue, Wang Jiancheng, Chen Gen
Spinal Cord Injury Rehabilitation Department, Rehabilitation Center Hospital of Gansu Province.
The Second Clinical Medical College of Lanzhou University.
Medicine (Baltimore). 2019 Sep;98(36):e17050. doi: 10.1097/MD.0000000000017050.
Hypertension is one of the most common chronic diseases and an increasingly public-health challenge worldwide. Previous meta-analyses evaluated the effects of azilsartan medoxomil compared to placebo or other antihypertensive drugs in patients with hypertension. However, it is still unclear which dose of azilsartan is optimal. This study will perform a network meta-analysis to assess the efficacy and safety of different doses of azilsartan medoxomil in patients with hypertension.
PubMed, EMBASE.com, the Cochrane library, Scopus, and Web of Science were searched from inception to May 2019. Randomized controlled trials reporting efficacy and safety of different doses of azilsartan medoxomil on hypertension will be included if they compared 1 dose of azilsartan medoxomil with another dose of azilsartan medoxomil or with a placebo. Risk of bias of the included trials will be evaluated according to the Cochrane Handbook 5.1.0. NMA will be performed in a Bayesian hierarchical framework using WinBUGS 14.
The results will be submitted to a peer-reviewed journal for publication.
This study will summarize all the available data to provide reliable evidence of the value of different doses of azilsartan medoxomil for the treatment of hypertension.
CRD42019136882.
高血压是最常见的慢性病之一，也是全球日益严峻的公共卫生挑战。既往的荟萃分析评估了阿齐沙坦酯与安慰剂或其他抗高血压药物相比对高血压患者的疗效。然而，尚不清楚哪种剂量的阿齐沙坦是最佳的。本研究将进行网状荟萃分析，以评估不同剂量阿齐沙坦酯对高血压患者的疗效和安全性。
检索PubMed、EMBASE.com、Cochrane图书馆、Scopus和Web of Science数据库，检索时间从建库至2019年5月。纳入比较1种剂量阿齐沙坦酯与另一种剂量阿齐沙坦酯或安慰剂的随机对照试验，这些试验报告了不同剂量阿齐沙坦酯对高血压的疗效和安全性。将根据Cochrane手册5.1.0评估纳入试验的偏倚风险。将使用WinBUGS 14在贝叶斯分层框架中进行网状荟萃分析。
研究结果将提交给同行评审期刊发表。
本研究将汇总所有可用数据，为不同剂量阿齐沙坦酯治疗高血压的价值提供可靠证据。
CRD42019136882。
